PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications.

Abstract Artesunate (AS) is the WHO first-line treatment of severe malaria in endemic countries, in adults and children. However, despite solid evidence that AS is safe and more effective than quinine in endemic areas, its deployment in non-endemic areas has been slow, due in part to the absence of a full good manufacturing practice (GMP) qualification (although prequalification has been granted in 2010). Prospective comparative trials were not conducted in travellers, but several retrospective studies and case reports are providing insights into the efficacy and safety of AS in imported severe malaria.
PMID
Related Publications

Delayed haemolysis after artesunate treatment of severe malaria - review of the literature and perspective.

Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia.

Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report.

Severe falciparum malaria treated with artesunate complicated by delayed onset haemolysis and acute kidney injury.

Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis.

Authors

Mayor MeshTerms
Keywords

Artesunate

anaemia

imported malaria

post-artesunate delayed haemolysis

travellers

Journal Title journal of travel medicine
Publication Year Start




PMID- 28395097
OWN - NLM
STAT- In-Process
DA  - 20170410
LR  - 20170410
IS  - 1708-8305 (Electronic)
IS  - 1195-1982 (Linking)
VI  - 24
IP  - 2
DP  - 2017 Mar 01
TI  - Artesunate to treat severe malaria in travellers: review of efficacy and safety
      and practical implications.
LID - 10.1093/jtm/taw093 [doi]
AB  - Background: Artesunate (AS) is the WHO first-line treatment of severe malaria in 
      endemic countries, in adults and children. However, despite solid evidence that
      AS is safe and more effective than quinine in endemic areas, its deployment in
      non-endemic areas has been slow, due in part to the absence of a full good
      manufacturing practice (GMP) qualification (although prequalification has been
      granted in 2010). Prospective comparative trials were not conducted in
      travellers, but several retrospective studies and case reports are providing
      insights into the efficacy and safety of AS in imported severe malaria. Methods: 
      We performed a systematic review on AS use in non-endemic areas for the treatment
      of imported severe malaria, using the Prisma method for bibliographic reports.
      Post-AS delayed haemolysis (PADH) was defined by delayed haemolytic episodes
      occurring 7-30 days after treatment initiation. We summarized prescription
      guidelines and generated answers to frequently asked questions regarding the use 
      of AS in travellers with severe malaria. Results: We analysed 12 retrospectives
      and 1 prospective study as well as 7 case reports of AS treatment in 624
      travellers. Of 574 patients with reported outcome, 23 died (4%). No death was
      attributed to AS toxicity. Non-haematological side effects were uncommon and
      mainly included mild hepatitis, neurological, renal, cutaneous and cardiac
      manifestations. PADH occurred in 15% of the treated patients. No death or
      sequelae were reported. Overall blood transfusion was administered in 50% of
      travellers with PADH. Conclusion: AS is highly efficacious in travellers with
      severe malaria. The frequency of PADH supports the need of weekly follow-up of
      haematological parameters during 1 month. Full GMP qualification for the drug and
      rapid approval by drug agencies is warranted, backed by clear recommendations for
      optimal use.
FAU - Roussel, Camille
AU  - Roussel C
AD  - Universite Sorbonne Paris Cite, Universite Paris Descartes, Inserm, INTS, Unite
      Biologie Integree du Globule Rouge, Laboratoire d'Excellence GR-Ex, Paris,
      France.
FAU - Caumes, Eric
AU  - Caumes E
AD  - Assistance Publique-Hopitaux de Paris, Hopital Pitie-Salpetriere, Service des
      Maladies Infectieuses et Tropicales, Paris, France.
AD  - Sorbonne Universite, Universite Pierre et Marie Curie, faculte de medecine
      Pitie-Salpetriere, Paris, France.
FAU - Thellier, Marc
AU  - Thellier M
AD  - Sorbonne Universite, Universite Pierre et Marie Curie, faculte de medecine
      Pitie-Salpetriere, Paris, France.
AD  - Centre National de Reference du Paludisme - Site Pitie-Salpetriere, Paris,
      France.
AD  - Assistance Publique-Hopitaux de Paris, Hopital Pitie-Salpetriere, Service de
      parasitologie, Paris, France.
FAU - Ndour, Papa Alioune
AU  - Ndour PA
AD  - Universite Sorbonne Paris Cite, Universite Paris Descartes, Inserm, INTS, Unite
      Biologie Integree du Globule Rouge, Laboratoire d'Excellence GR-Ex, Paris,
      France.
FAU - Buffet, Pierre A
AU  - Buffet PA
AD  - Universite Sorbonne Paris Cite, Universite Paris Descartes, Inserm, INTS, Unite
      Biologie Integree du Globule Rouge, Laboratoire d'Excellence GR-Ex, Paris,
      France.
FAU - Jaureguiberry, Stephane
AU  - Jaureguiberry S
AD  - Assistance Publique-Hopitaux de Paris, Hopital Pitie-Salpetriere, Service des
      Maladies Infectieuses et Tropicales, Paris, France.
AD  - Sorbonne Universite, Universite Pierre et Marie Curie, faculte de medecine
      Pitie-Salpetriere, Paris, France.
AD  - Centre National de Reference du Paludisme - Site Pitie-Salpetriere, Paris,
      France.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Travel Med
JT  - Journal of travel medicine
JID - 9434456
OTO - NOTNLM
OT  - Artesunate
OT  - anaemia
OT  - imported malaria
OT  - post-artesunate delayed haemolysis
OT  - travellers
EDAT- 2017/04/11 06:00
MHDA- 2017/04/11 06:00
CRDT- 2017/04/11 06:00
PHST- 2016/11/28 [accepted]
AID - 2930768 [pii]
AID - 10.1093/jtm/taw093 [doi]
PST - ppublish
SO  - J Travel Med. 2017 Mar 1;24(2). doi: 10.1093/jtm/taw093.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>